Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
AC Immune SA
AC Immune SA
Activities:
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
How advanced technologies are unlocking the future of drug manufacturing
As the drug production landscape changes, it opens the door to pursue hybrid opportunities that push the boundaries of technological advancement in the field, reports Jon...
Andelyn Biosciences and Grace Science, LLC partner to manufacture AAV gene therapy
The partnership will seek to maximise programme efficiency, support the ongoing clinical trial and accelerate this critical therapy to patients
Teva UK and Closed Loop Medicine partner to advance personalised medicine development
SaMD platform aims to advance personalised medicine development, improve drug efficacy and patient outcomes with specific chronic conditions
Henkel facilities receive EXCiPACT certificate as suppliers of pharmaceutical excipients
The certification means Henkel meets EXCiPACT’s guidelines for good manufacturing practice (GMP) and good distribution practice (GDP)
Upcoming event
BioProcess International Europe
9-12 April 2024 | Exhibition | RAI Amsterdam
See all
Related Content
Manufacturing
AC Immune strengthens management, appoints Madiha Derouazi as CSO and Christopher Roberts as CFO
Retiring CSO Dr. Marie Kosco-Vilbois will remain as consultant to ensure smooth handover
Pharmaceutical
AC Immune SA appoints Dr Marie Kosco-Vilbois
Neurodegenerative Disease company has new Chief Scientific Officer
Pharmaceutical
New strategic partnership focuses on Alzheimers
Swiss AC Immune and Chinese WuXi Biologics sign agreement
Research & Development
AC Immune and Lilly announce licence and collaboration agreement
Multi-year agreement focuses on Morphomer tau aggregation inhibitors, for the potential treatment of Alzheimer's disease and other neurodegenerative diseases
Pharmaceutical
Landmark for AC Immune Alzheimer and Down Syndrome vaccines
The swiss clinical stage biopharmaceutical company has a broad pipeline focused on neurodegenerative diseases
Subscribe now